HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Souria Dougherty Selected Research

imetelstat

7/2022Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
10/2021Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
1/2021Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Souria Dougherty Research Topics

Disease

2Primary Myelofibrosis (Myelosclerosis)
07/2022 - 10/2021
2Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2021 - 10/2015
1Thrombocytopenia (Thrombopenia)
10/2015

Drug/Important Bio-Agent (IBA)

3imetelstatIBA
07/2022 - 01/2021
2Telomerase (Telomerase Reverse Transcriptase)IBA
07/2022 - 10/2021
1Janus Kinase InhibitorsIBA
07/2022
1Biomarkers (Surrogate Marker)IBA
10/2021
1Phosphotransferases (Kinase)IBA
10/2021
1HematinicsIBA
01/2021
1eltrombopagFDA Link
10/2015

Therapy/Procedure

1Therapeutics
10/2015